Get the Stockscreener App
3.57
3.51%
-0.13
Annexon Inc Stock (ANNX) Latest News
Check out these key findings about Annexon Inc (ANNX) - SETE News
Annexon Inc [ANNX] Investment Guide: What You Need to Know - Knox Daily
A year in review: Annexon Inc (ANNX)’s performance in the last year - US Post News
Market Update: Annexon Inc (ANNX) Sees Negative Movement, Closing at 3.52 - The Dwinnex
Analyzing the Impact of Earnings Reports on Annexon Inc Inc. (ANNX) Price Performance - The InvestChronicle
Annexon, Inc. (NASDAQ:ANNX) Short Interest Up 23.7% in January - MarketBeat
Annexon (NASDAQ:ANNX) and Tonix Pharmaceuticals (NASDAQ:TNXP) Head-To-Head Comparison - Defense World
What's Driving These Stocks Higher In After-hours? - RTTNews
Vanguard Group Inc's Strategic Acquisition of Annexon Inc Shares - GuruFocus.com
Annexon stock touches 52-week low at $3.85 amid market challenges - Investing.com Canada
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals - MSN
Cantor Fitzgerald Estimates Annexon FY2025 Earnings - Defense World
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of “Buy” by Brokerages - Defense World
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Guillain-Barré Syndrome Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Chafic Karam, Hansa Biopharma AB, Annexon - The Globe and Mail
Guillain-Barre Syndrome Market to Reach New Heights in Growth - openPR
Annexon (NASDAQ: ANNX) Issues Press Release Outlining 2025 Outlook - Defense World
Hennion & Walsh Asset Management Inc. Boosts Position in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Barclays PLC Boosts Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Barclays PLC Acquires 120,789 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year - GlobeNewswire
Annexon Advances Three Breakthrough Therapies, Including First Targeted GBS Treatment - StockTitan
JPMorgan Chase & Co. Has $10.10 Million Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Expands Board with Appointment of New Member William Jones - Defense World
Annexon Biosciences Strengthens Board for Strategic Growth - TipRanks
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones - GlobeNewswire
Annexon Strengthens Board with Commercial Veteran BJ Jones Ahead of Late-Stage Drug Launches - StockTitan
ANNXAnnexon, Inc. Latest Stock News & Market Updates - StockTitan
Jane Street Group LLC Sells 39,601 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon: Breakthrough In Guillain-Barré Faces Upcoming FDA Hurdles (NASDAQ:ANNX) - Seeking Alpha
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Annexon (NASDAQ:ANNX) Stock Price Down 4.3%Here's Why - MarketBeat
Franklin Resources Inc. Acquires Shares of 49,406 Annexon, Inc. (NASDAQ:ANNX) - Defense World
Barclays PLC Has $1.05 Million Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Geode Capital Management LLC Grows Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by State Street Corp - Defense World
Annexon (ANNX) Surges with Promising Phase 3 Results for Guillain-Barré Syndrome Treatment - TipRanks
State Street Corp Has $22.74 Million Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon (NASDAQ:ANNX) Shares Down 3.8%Time to Sell? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Annexon (NASDAQ:ANNX) - Defense World
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):